Effects of recombinant human endostatin combined with intraleural injection of cisplatin on patients with non-small cell lung cancer complicated with blood pleural effusion

Abstract

Objective To investigate the effects of recombinant human endostatin combined with intraleural injection of cisplatin in the treatment of non-small cell lung cancer complicated with blood pleural effusion. Methods Forty patients with non-small cell lung cancer complicated with bloody pleural effusion treated in Xinzhou People’s Hospital from January 2012 to December 2017 were selected. And they were divided into study group and control group according to the random number table method, with 20 cases in each group. The control group was treated with intrapleural injection of cisplatin, while the observation group was treated with recombinant human endostatin and cisplatin. The total efficacy and serum tumor markers, such as carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) were compared between the two groups. Results The total effective rate of the observation group was 80% (16/20), higher than 35% (7/20) of the control group (P 0.05). However, the serum tumor markers were improved in the two groups after treatment, and the improvement of the observation group was better than that of the control group (P 0.05). The 1-year survival rate of the observation group was 70% (14/20), higher than 35% (7/20) of the control group (P<0.05). Conclusions Recombinant human endostatin combined with cisplatin in the treatment of non-small cell lung cancer complicated with blood pleural effusion can improve the total effective rate and levels of serum tumor markers, with high safety. Key words: Non-small cell lung cancer; Bloody pleural effusion; Cisplatin; Recombinant human endostatin; Intrathoracic injection